HeraMED

HeraMED Quick Ratio

The Quick Ratio (Acid Test) of HeraMED (HMD.AX) as of Nov 16, 2026 is 3.17. In the previous year, Quick Ratio (Acid Test) was 0.71 — a change of 344.42% (higher).

Quick Ratio

3.17

YoY

344.42%

Last updated:

Quick Ratio (Acid Test) of HeraMED is 2024 3.17 . Quick Ratio (Acid Test) of HeraMED was 2023 0.71 . It decreases by 344.42% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HeraMED Stock analysis

What does HeraMED do? HeraMED Ltd. generates revenue through the sale of hardware solutions and related software applications. Its flagship product, HeraBEAT, is a medical-grade, clinically-validated connected Ultrasound Fetal Doppler device designed for expectant mothers to self-monitor their fetus' heart rate at home. The device connects via Bluetooth Low Energy to smartphones, transmitting data to a dedicated app that displays readings. The company also offers a homecare pregnancy solution service, leveraging AI and machine-learning algorithms to analyze fetal data and provide insights to healthcare professionals or home users. Sales are primarily directed to expectant mothers seeking home monitoring tools and healthcare providers integrating these solutions into patient care. HeraBEAT is marketed as a clinically-validated tool for home use, distinguishing it from standard consumer devices. The product’s integration with smartphone applications enables real-time data access, appealing to tech-savvy parents. The homecare pregnancy solution complements the hardware by offering ongoing support through AI-driven analysis, enhancing user engagement and retention. Healthcare professionals benefit from the data insights provided, potentially incorporating HeraBEAT into routine prenatal care protocols. The company’s revenue streams are built around direct sales of HeraBEAT devices and subscription-based services tied to the homecare solution. Expectant mothers purchase the hardware and access the software interface, while healthcare providers may adopt the service model for patient monitoring. AI and machine-learning capabilities are embedded in the product offering, positioning HeraMED as a provider of both medical devices and data-driven health services. HeraMED is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HeraMED stock

Quick Ratio (Acid Test) of HeraMED is 3.17 in 2024.

Quick Ratio (Acid Test) of HeraMED changed from 0.71 to 3.17, representing a 344.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) HeraMED since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s HeraMED with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — HeraMED

All Key Metrics — HeraMED